Literature DB >> 35040886

Trends in US Ambulatory Care Patterns During the COVID-19 Pandemic, 2019-2021.

John N Mafi1,2, Melody Craff3, Sitaram Vangala1, Thomas Pu3, Dale Skinner3, Cyrus Tabatabai-Yazdi4, Anikia Nelson3, Rachel Reid2,5, Denis Agniel2, Chi-Hong Tseng1, Catherine Sarkisian1, Cheryl L Damberg2, Katherine L Kahn1,2.   

Abstract

Importance: Following reductions in US ambulatory care early in the pandemic, it remains unclear whether care consistently returned to expected rates across insurance types and services. Objective: To assess whether patients with Medicaid or Medicare-Medicaid dual eligibility had significantly lower than expected return to use of ambulatory care rates than patients with commercial, Medicare Advantage, or Medicare fee-for-service insurance. Design, Setting, and Participants: In this retrospective cohort study examining ambulatory care service patterns from January 1, 2019, through February 28, 2021, claims data from multiple US payers were combined using the Milliman MedInsight research database. Using a difference-in-differences design, the extent to which utilization during the pandemic differed from expected rates had the pandemic not occurred was estimated. Changes in utilization rates between January and February 2020 and each subsequent 2-month time frame during the pandemic were compared with the changes in the corresponding months from the year prior. Age- and sex-adjusted Poisson regression models of monthly utilization counts were used, offsetting for total patient-months and stratifying by service and insurance type. Exposures: Patients with Medicaid or Medicare-Medicaid dual eligibility compared with patients with commercial, Medicare Advantage, or Medicare fee-for-service insurance, respectively. Main Outcomes and Measures: Utilization rates per 100 people for 6 services: emergency department, office and urgent care, behavioral health, screening colonoscopies, screening mammograms, and contraception counseling or HIV screening.
Results: More than 14.5 million US adults were included (mean age, 52.7 years; 54.9% women). In the March-April 2020 time frame, the combined use of 6 ambulatory services declined to 67.0% (95% CI, 66.9%-67.1%) of expected rates, but returned to 96.7% (95% CI, 96.6%-96.8%) of expected rates by the November-December 2020 time frame. During the second COVID-19 wave in the January-February 2021 time frame, overall utilization again declined to 86.2% (95% CI, 86.1%-86.3%) of expected rates, with colonoscopy remaining at 65.0% (95% CI, 64.1%-65.9%) and mammography at 79.2% (95% CI, 78.5%-79.8%) of expected rates. By the January-February 2021 time frame, overall utilization returned to expected rates as follows: patients with Medicaid at 78.4% (95% CI, 78.2%-78.7%), Medicare-Medicaid dual eligibility at 73.3% (95% CI, 72.8%-73.8%), commercial at 90.7% (95% CI, 90.5%-90.9%), Medicare Advantage at 83.2% (95% CI, 81.7%-82.2%), and Medicare fee-for-service at 82.0% (95% CI, 81.7%-82.2%; P < .001; comparing return to expected utilization rates among patients with Medicaid and Medicare-Medicaid dual eligibility, respectively, with each of the other insurance types). Conclusions and Relevance: Between March 2020 and February 2021, aggregate use of 6 ambulatory care services increased after the preceding decrease in utilization that followed the onset of the COVID-19 pandemic. However, the rate of increase in use of these ambulatory care services was significantly lower for participants with Medicaid or Medicare-Medicaid dual eligibility than for those insured by commercial, Medicare Advantage, or Medicare fee-for-service.

Entities:  

Mesh:

Year:  2022        PMID: 35040886      PMCID: PMC8767442          DOI: 10.1001/jama.2021.24294

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   157.335


  18 in total

1.  Excess Deaths From COVID-19 and Other Causes in the US, March 1, 2020, to January 2, 2021.

Authors:  Steven H Woolf; Derek A Chapman; Roy T Sabo; Emily B Zimmerman
Journal:  JAMA       Date:  2021-04-02       Impact factor: 56.272

2.  Pinching the poor? Medicaid cost sharing under the ACA.

Authors:  Brendan Saloner; Lindsay Sabik; Benjamin D Sommers
Journal:  N Engl J Med       Date:  2014-03-27       Impact factor: 91.245

3.  Trends in Outpatient Care Delivery and Telemedicine During the COVID-19 Pandemic in the US.

Authors:  Sadiq Y Patel; Ateev Mehrotra; Haiden A Huskamp; Lori Uscher-Pines; Ishani Ganguli; Michael L Barnett
Journal:  JAMA Intern Med       Date:  2020-11-16       Impact factor: 21.873

4.  Association of Stratification by Dual Enrollment Status With Financial Penalties in the Hospital Readmissions Reduction Program.

Authors:  Karen E Joynt Maddox; Mat Reidhead; Andrew C Qi; David R Nerenz
Journal:  JAMA Intern Med       Date:  2019-06-01       Impact factor: 21.873

5.  Changes in US Medicaid Enrollment During the COVID-19 Pandemic.

Authors:  Peggah Khorrami; Benjamin D Sommers
Journal:  JAMA Netw Open       Date:  2021-05-03

6.  Excess Deaths From COVID-19 and Other Causes, March-April 2020.

Authors:  Steven H Woolf; Derek A Chapman; Roy T Sabo; Daniel M Weinberger; Latoya Hill
Journal:  JAMA       Date:  2020-08-04       Impact factor: 157.335

7.  Cancer Care Disparities during the COVID-19 Pandemic: COVID-19 and Cancer Outcomes Study.

Authors:  Andrew L Schmidt; Ziad Bakouny; Sheena Bhalla; John A Steinharter; Douglas A Tremblay; Mark M Awad; Alaina J Kessler; Robert I Haddad; Michelle Evans; Fiona Busser; Michael Wotman; Catherine R Curran; Brittney S Zimmerman; Gabrielle Bouchard; Tomi Jun; Pier V Nuzzo; Qian Qin; Laure Hirsch; Jonathan Feld; Kaitlin M Kelleher; Danielle Seidman; Hsin-Hui Huang; Heather M Anderson-Keightly; Sarah Abou Alaiwi; Talia D Rosenbloom; Penina S Stewart; Matthew D Galsky; Toni K Choueiri; Deborah B Doroshow
Journal:  Cancer Cell       Date:  2020-11-03       Impact factor: 31.743

8.  Disparities in quality of cancer care: The role of health insurance and population demographics.

Authors:  Arti Parikh-Patel; Cyllene R Morris; Kenneth W Kizer
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

9.  Disparities in outpatient visits for mental health and/or substance use disorders during the COVID surge and partial reopening in Massachusetts.

Authors:  Jie Yang; Mary Beth Landrum; Li Zhou; Alisa B Busch
Journal:  Gen Hosp Psychiatry       Date:  2020-10-12       Impact factor: 3.238

10.  The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study.

Authors:  Camille Maringe; James Spicer; Melanie Morris; Arnie Purushotham; Ellen Nolte; Richard Sullivan; Bernard Rachet; Ajay Aggarwal
Journal:  Lancet Oncol       Date:  2020-07-20       Impact factor: 54.433

View more
  5 in total

1.  Delay of routine health care during the COVID-19 pandemic: A theoretical model of individuals' risk assessment and decision making.

Authors:  Prakriti Shukla; Myeong Lee; Samantha A Whitman; Kathleen H Pine
Journal:  Soc Sci Med       Date:  2022-06-22       Impact factor: 5.379

2.  Coronavirus Disease 2019, Universal Health Coverage, and Ambulatory Care in 2020.

Authors:  Esra E Bayindir; Jonas Schreyögg
Journal:  Med Care       Date:  2022-04-19       Impact factor: 3.178

3.  Association Between Primary Care Practice Telehealth Use and Acute Care Visits for Ambulatory Care-Sensitive Conditions During COVID-19.

Authors:  Kathleen Y Li; Sophia Ng; Ziwei Zhu; Jeffrey S McCullough; Keith E Kocher; Chad Ellimoottil
Journal:  JAMA Netw Open       Date:  2022-03-01

4.  Association between Covid-19 Vaccination and Influenza Vaccination Rates.

Authors:  Richard K Leuchter; Nicholas J Jackson; John N Mafi; Catherine A Sarkisian
Journal:  N Engl J Med       Date:  2022-06-15       Impact factor: 176.079

5.  Trends in the Volume and Types of Primary Care Visits during the Two Years of the COVID-19 Pandemic in Israel.

Authors:  Oren Miron; Yael Wolff Sagy; Shlomit Yaron; Noga Ramot; Gil Lavie
Journal:  Int J Environ Res Public Health       Date:  2022-08-25       Impact factor: 4.614

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.